Camurus AB (CAMX) AI Stock Analysis

• Market Cap: $36.22B
• Dividend Yield: N/A
• Average Volume (3M): 269.61K
• Price to Earnings (P/E): 65.1
• Beta (1Y): 0.70
• Revenue Growth: 11.69%
• EPS Growth: 15.57%
• Country: SE
• Employees: 238
• Sector: Healthcare
• Sector Strength: 46
• Industry: Biotechnology
• EPS (TTM): 3.35
• Shares Outstanding: 59,626,984
• 10 Day Avg. Volume: 397,862
• 30 Day Avg. Volume: 269,607
• PEG Ratio: -1.56
• Price to Book (P/B): 13.98
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 140.09
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 73 Outperform
• Price Target: kr662.00 ▲(8.97%Upside)

Camurus AB's strong financial performance is the most significant factor, bolstered by robust revenue growth and financial stability. However, the high P/E ratio suggests potential overvaluation, which weighs on the overall score. Technical analysis indicates mixed signals, with the stock near its 100-day moving average and neutral RSI, contributing to a moderate overall score.

Camurus AB Business Overview & Revenue Model

Company Description

Camurus AB (publ), a pharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, Japan, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence; episil oral liquid, a medical device for the treatment of inflammatory and painful conditions in the oral cavity; and Brixadi to treat opioid use disorder Its products pipeline also includes CAM2038 for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; CAM2047 for the treatment of chemotherapy-induced nausea and vomiting that is in phase 1 clinical trial; and CAM2048, which is in phase I clinical trial for postoperative pain. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.

How the Company Makes Money

Camurus AB generates revenue through the sales and licensing of its pharmaceutical products. The company's proprietary FluidCrystal technology serves as a platform for developing long-acting injectable treatments, which are licensed to other pharmaceutical companies, thereby generating licensing fees and royalties. Additionally, Camurus markets its own products, such as Buvidal, which is used for the treatment of opioid dependence, directly contributing to its revenue. Significant partnerships with healthcare providers and pharmaceutical companies also play a crucial role in extending the reach of its products, further supporting its financial performance.

Camurus AB Financial Statement Overview

Summary

Camurus AB demonstrates strong financial performance with significant revenue growth, efficient cost management, and robust cash flow generation. The balance sheet is stable with low debt levels and a high equity ratio, although there is slight pressure on profitability margins.

Income Statement

Camurus AB has demonstrated strong revenue growth from 2019 to 2024, with total revenue increasing from 105.6 million SEK to 1,867.6 million SEK, indicating a robust growth trajectory. The gross profit margin has remained high, reaching 93.1% in 2024, which highlights efficient cost management. However, the net profit margin has slightly decreased to 22.9% in 2024 from 25.1% in 2023, suggesting some pressure on profitability. The company has improved its EBIT and EBITDA margins significantly over the years, reflecting better operational efficiency.

Balance Sheet

The balance sheet shows a strong equity position with a high equity ratio of 87.5% in 2024, indicating financial stability and low reliance on debt. The debt-to-equity ratio is low at 0.005, reflecting minimal leverage risk. Return on equity (ROE) is impressive at 13.0%, highlighting effective utilization of equity to generate profits. Overall, the balance sheet presents a stable financial position with low debt and strong equity.

Cash Flow

Camurus AB has shown a positive trend in free cash flow, with a significant increase from -430.3 million SEK in 2019 to 358.6 million SEK in 2024. The operating cash flow to net income ratio is 0.91 in 2024, indicating efficient cash generation relative to net income. The free cash flow to net income ratio also stands at 0.84, reflecting the company's ability to convert net income into free cash flow. However, there was a substantial decrease in operating cash flow from 606.9 million SEK in 2023 to 388.0 million SEK in 2024, which could be a concern moving forward.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.87B	1.72B	956.34M	600.57M	336.00M
Gross Profit	1.74B	1.59B	853.08M	515.22M	300.71M
EBITDA	568.24M	562.54M	87.59M	-97.72M	-196.58M
Net Income	428.39M	431.44M	55.55M	-90.45M	-167.26M
Balance Sheet
Total Assets	3.76B	1.91B	1.31B	1.08B	1.04B
Cash, Cash Equivalents and Short-Term Investments	2.85B	1.19B	565.54M	411.57M	461.79M
Total Debt	17.04M	24.51M	26.22M	25.66M	25.48M
Total Liabilities	467.33M	414.82M	310.82M	232.99M	196.66M
Stockholders Equity	3.29B	1.49B	994.67M	848.91M	847.44M
Cash Flow
Free Cash Flow	358.62M	596.75M	99.29M	-148.37M	-242.16M
Operating Cash Flow	387.99M	606.88M	101.20M	-143.43M	-238.83M
Investing Cash Flow	-29.37M	-10.13M	5.38M	-4.94M	-3.33M
Financing Cash Flow	1.30B	28.76M	43.70M	98.90M	347.85M

Camurus AB Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 607.50
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:CAMX, the sentiment is Positive. The current price of 607.5 is above the 20-day moving average (MA) of 591.60, above the 50-day MA of 586.19, and above the 200-day MA of 596.94, indicating a bullish trend. The MACD of 5.35 indicates Positive momentum. The RSI at 55.49 is Neutral, neither overbought nor oversold. The STOCH value of 58.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:CAMX.

Camurus AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CAMX	73 Outperform	$36.22B	65.05	17.31%	―	11.69%	15.57%
Sector *	51 Neutral	$7.41B	0.36	-61.88%	2.34%	16.99%	1.69%
HNSA	51 Neutral	kr2.28B	―		―	9.53%	41.19%
B9A		€1.45B	17.30	60.96%	―	―	―
8F8		€82.41M	―	-48.22%	―	―	―
7XB		€34.72M	―	-47.73%	―	―	―
6XP		€126.21M	―	-42.24%	―	―	―

Camurus AB Corporate Events

Camurus’ POSITANO Study Shows Promising Results for PLD Treatment

Camurus announced positive results from its POSITANO Phase 2b study, which evaluated the efficacy and safety of CAM2029 in patients with polycystic liver disease (PLD). The study demonstrated that CAM2029 significantly reduces liver and cyst volume compared to placebo and improves symptoms, addressing a high unmet medical need in PLD treatment. Following these results, Camurus plans to discuss a Phase 3 study with regulatory authorities, potentially enhancing its positioning in the biopharmaceutical industry and offering hope to PLD patients.

The most recent analyst rating on (SE:CAMX) stock is a Buy with a SEK710.00 price target. To see the full list of analyst forecasts on Camurus AB stock, see the SE:CAMX Stock Forecast page.

Camurus Partners with Eli Lilly for Long-Acting Incretin Therapies

Camurus has entered a collaboration and license agreement with Eli Lilly, granting Lilly exclusive rights to develop and commercialize long-acting incretin products for cardiometabolic health using Camurus’ FluidCrystal technology. This partnership could bring Camurus up to $870 million in milestone payments and royalties, enhancing its market presence in the rapidly expanding field of metabolic diseases while allowing it to maintain its focus on CNS and rare diseases.

The most recent analyst rating on (SE:CAMX) stock is a Buy with a SEK710.00 price target. To see the full list of analyst forecasts on Camurus AB stock, see the SE:CAMX Stock Forecast page.

Camurus Executes Share Repurchase to Support Incentive Plan

Camurus’ Board of Directors has exercised its authorization to repurchase shares as part of its commitment to the Performance Share Plan 2025/2028. This strategic move involves the repurchase and conversion of 240,000 series C shares into common shares, effectively doubling the company’s holdings of common shares to 480,000, which is expected to enhance the company’s operational flexibility and shareholder value.

The most recent analyst rating on (SE:CAMX) stock is a Buy with a SEK710.00 price target. To see the full list of analyst forecasts on Camurus AB stock, see the SE:CAMX Stock Forecast page.

Camurus AB Annual General Meeting 2025: Key Resolutions and Strategic Initiatives

Camurus AB held its annual general meeting where key resolutions were passed, including the re-election of board members and the election of new members, as well as the approval of fees for board and committee members. The meeting also authorized the board to issue new shares and convertibles, acquire and transfer the company’s own shares, and implement a Performance Share Plan for employees. These resolutions aim to enhance Camurus’ strategic flexibility and align employee incentives with company performance, potentially impacting its market positioning and stakeholder interests.

The most recent analyst rating on (SE:CAMX) stock is a Buy with a SEK710.00 price target. To see the full list of analyst forecasts on Camurus AB stock, see the SE:CAMX Stock Forecast page.

Camurus Reports Strong Q1 2025 Performance with Significant Revenue Growth

Camurus reported a strong first quarter in 2025, with total revenues increasing by 43% to SEK 558 million and product sales rising by 33% to SEK 485 million. The company also saw a significant 162% rise in profit before tax. Key developments included regulatory approval for Buvidal in Serbia and new launches in Switzerland and Luxembourg, along with the initiation of a Phase 1 clinical study for a new semaglutide depot. The positive CHMP opinion for Oczyesa® in the EU marks a significant advancement for Camurus, potentially enhancing its market positioning and stakeholder value.

The most recent analyst rating on (SE:CAMX) stock is a Buy with a SEK750.00 price target. To see the full list of analyst forecasts on Camurus AB stock, see the SE:CAMX Stock Forecast page.

Camurus Appoints New CFO to Drive Growth and Diversification

Camurus has appointed Anders Vadsholt as its new Chief Financial Officer, effective July 1, 2025. Vadsholt brings significant financial and M&A experience from the biotech and pharmaceutical sectors, having previously served as CFO for Orphazyme A/S and Topotarget A/S. This strategic appointment is expected to support Camurus’ continued growth and diversification, enhancing its position in the biopharmaceutical industry. The transition is set to be smooth, with outgoing CFO Jon Garay Alonso remaining until August to facilitate the change.

The most recent analyst rating on (SE:CAMX) stock is a Buy with a SEK710.00 price target. To see the full list of analyst forecasts on Camurus AB stock, see the SE:CAMX Stock Forecast page.